Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Scholar Rock Holding Corp | Director | Common Stock | 38.6K | $608K | $15.74 | May 9, 2024 | Direct |
Morphic Holding, Inc. | Director | Common Stock | 0 | $0 | $55.79 | Aug 16, 2024 | By Polaris Entrepreneurs' Fund VII, L.P. |
Morphic Holding, Inc. | Director | Common Stock | 0 | $0 | $55.79 | Aug 16, 2024 | By Polaris Partners VII, L.P. |
Morphic Holding, Inc. | Director | Common Stock | 0 | $0 | $55.79 | Aug 16, 2024 | Direct |
Scholar Rock Holding Corp | Director | Common Stock | 0 | $0 | $15.74 | May 9, 2024 | Indirect |
Camp4 Therapeutics Corp | Director, 10%+ Owner | Common Stock | 909K | Oct 15, 2024 | Indirect | ||
Scholar Rock Holding Corp | Director | Stock Option (Right to Buy) | 36K | Jun 21, 2023 | Direct | ||
Syros Pharmaceuticals, Inc. | Director | Stock Option (right to buy) | 17.5K | Jun 1, 2022 | Direct | ||
Metacrine, Inc. | Director, 10%+ Owner | Stock Option (right to buy) | 16.5K | May 18, 2022 | Direct | ||
Camp4 Therapeutics Corp | Director, 10%+ Owner | Series A Prime Preferred Stock | 0 | Oct 15, 2024 | Indirect | ||
Camp4 Therapeutics Corp | Director, 10%+ Owner | Series B Preferred Stock | 0 | Oct 15, 2024 | Indirect | ||
Morphic Holding, Inc. | Director | Stock Option (Right to Buy) | 0 | Aug 16, 2024 | Direct |